NCT00367913

Clarithromycin v Ciprofloxacin Added to Rifampicin + Ethambutol, for Opportunist Mycobacterial Pulmonary Disease

Treatment of Pulmonary Disease Caused by MAIS, M.Xenopi or M.Malmoense: A Comparison of Two Triple Drug Regimens and an Assessment of the Value of Immunotherapy With M.Vaccae

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 400 (planned)
• Sponsor: British Thoracic Society · Academic / Other
• Sex: All
• Age: 16 Years
• Healthy volunteers: Not accepted

Summary

To date key drugs in the treatment of MAIS, M.malmoense and M.xenopi (Opportunist Mycobacteria have been rifampicin and ethambutol. Clarithromycin and Ciprofloxacin are active in vitro against these species of mycobacteria. The primary aim of this study was to compare these to agents as supplements to rifampicin and ethambutol. A secondary aim was to assess the vale of immunotherapy with M.vaccae.

Conditions

• Pulmonary Diseases

Interventions

Type	Name	Description
DRUG	Addition of clarithromycin to rifampicin and ethambutol
DRUG	Addition of Ciprofloxacin to rifampicin and ethambutol
BIOLOGICAL	Vaccination with M.vaccae

Timeline

• Start date: 1995-03-01
• Completion: 2004-09-01
• First posted: 2006-08-23
• Last updated: 2006-08-23

Locations

1 site across 1 country: United Kingdom